SEC Sues Two for Insider Trading of Sequenom and Exact Sciences Shares | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Securities and Exchange Commission is suing two individuals alleging they illegally profited from insider trading of Sequenom and Exact Sciences' stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.